Company: PAII-WT
Filing Date: 2025-05-29
Form Type: DRS
Source: 0001213900-25-049013
Chunk: 328

Company: Pyrophyte Acquisition Corp. II
Filing Date: 2025-05-29
Form: DRS
Chunk 328
---
 and to other conditions. The underwriters are obligated to purchase all the units (other than those covered by the over -allotmentoption described below) if they purchase any of them. Units sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. If all the units are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. UBS has advised us that the underwriters do not intend to make sales to discretionary accounts. The offering of the units by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part. If the underwriters sell more units than the total number set forth in the table above, we have granted them an option, exercisable for 45 days from the date of this prospectus, to purchase up to 2,625,000 additional units at the initial public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus. The underwriters may exercise this option solely for the purpose of covering over -allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase a number of additional units approximately proportionate to that underwriter’s initial purchase commitment. Any units issued or sold under the option will be issued and sold on the same terms and conditions as the other units that are the subject of this offering. We, our sponsor and our officers and directors have agreed that, for a period of 180 days from the date of this prospectus, we and they will not, without the prior written consent of UBS, offer, sell, contract to sell, pledge, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any units, warrants, ordinary shares or any other securities convertible into, or exercisable or exchangeable for, units, warrants or ordinary shares; provided, however, that we may (1) issue and sell the private placement warrants, (2) issue and sell the additional units to cover our underwriters’ over -allotmentoption (if any), (3) register with the SEC pursuant to an, agreement to be entered into concurrently with the issuance and sale of the securities in this offering, the resale of the founder shares and the private